

ASX Release 18th September 2017

ePAT Technologies Limited
ABN 21 146 035 127
Suite 401, 35 Lime Street, Sydney, NSW, 2000
Registered Office: Suite 5, 95 Hay Street Subiaco WA 6008
Phone +61 8 9388 8290

ePAT Raises \$3.75 million via Heavily Subscribed Placement

ePAT Technologies Ltd is pleased to announce that firm acceptances have been received for the placement of 75,000,000 shares at 5 cents per share to raise \$3,750,000 before costs. The new shares will be issued pursuant to the Company's 15% placement capacity to professional and sophisticated investors. Patersons Securities Limited acted as the lead broker to the issue and the new investors include a family office and an institutional investor.

ePAT's Managing Director Philip Daffas said "During the past months we have achieved all our key milestones for 2017 ahead of schedule. In addition we have successfully negotiated a global perpetual license for exclusive access to the nViso facial emotion artificial intelligence and a first commercial agreement with Dementia Support Australia.

In doing so, we have also generated strong interest for the ePAT Dementia App within residential aged care and community care in the Australian and UK markets.


This new capital, together with our existing capital, will provide the runway and create the certainty required to accelerate the commercialization of the ePAT Dementia App with these customer groups, in Australia commencing Q4 2017 and in Europe from Q2 2018. This includes fast tracking new recruitment in the area of sales and clinical support.

In addition, this combined capital will support the Dementia App FDA approval process and the development and commercialization of the Kids App during 2018".


About ePAT:

ePAT Technologies Limited is an Australian based company that has developed mobile medical applications to provide pain assessment for individuals who are unable to communicate verbally with their carers.

ePAT's technology, a mobile application, the ePAT App*, uses cameras in smartphones and tablets to capture a brief video of the person, which is analysed in real time using facial emotion software to detect the presence of facial micro- expressions that are indicative of the presence of pain.



ePAT artificial intelligence assesses facial micro-expressions that are indicative of the presence of pain



The ePAT App six domains of pain assessment that calculates pain severity score

This data is then combined with other indicators of pain, such as vocalisations, behaviours and movements captured through the ePAT App to calculate a pain severity score. Due to its ease of use and its reproducibility, the ePAT App will be able to be used in the first instance to detect and measure a person's pain, and then further measurements can be used to monitor the effectiveness of pain management.

The ePAT App will be rolled out globally in two phases: first, the ePAT App for Dementia for people who are unable to communicate effectively, and second, the ePAT App for Children who have not yet learnt to speak.

*The ePAT App is a Class 1 Medical Device that has TGA (Australia) and CE mark (Europe Economic Area) regulatory clearance.

For further information, please contact:

Ian Hobson
Company Secretary
Tel: +61 8 9388 8290

Philip Daffas
Managing Director
Tel: +61 406-537-235